{
  "files": [
    {
      "assay": "HIC Retention Time (Min)a",
      "category": "aggregation",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophyscial_HICRT.csv",
      "path": "../data/aggregation/jain2017biophyscial_HICRT.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "Affinity-Capture Self-Interaction Nanoparticle Spectroscopy (AC-SINS) delta lambda max (nm) Average",
      "category": "aggregation",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_ACSINS.csv",
      "path": "../data/aggregation/jain2017biophysical_ACSINS.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "CSI-BLI Delta Response (nm)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_CSIBLI.csv",
      "path": "../data/aggregation/jain2017biophysical_CSIBLI.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "Slope for Accelerated Stability",
      "category": "aggregation",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_SAS.csv",
      "path": "../data/aggregation/jain2017biophysical_SAS.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "SGAC-SINS AS100 ((NH4)2SO4 mM)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_SGACSINS.csv",
      "path": "../data/aggregation/jain2017biophysical_SGACSINS.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "AC-SINS delta lambda max (nm)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_ACSINS.csv",
      "path": "../data/aggregation/jain2024assessment_ACSINS.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "CIC Column K",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_CIC.csv",
      "path": "../data/aggregation/jain2024assessment_CIC.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "CS-SINS (ave)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_CSSINS.csv",
      "path": "../data/aggregation/jain2024assessment_CSSINS.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "Fab.pI",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_Fab_pI.csv",
      "path": "../data/aggregation/jain2024assessment_Fab_pI.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "HIC RT (min)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_HIC.csv",
      "path": "../data/aggregation/jain2024assessment_HIC.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "SEC % Monomer",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_SEC.csv",
      "path": "../data/aggregation/jain2024assessment_SEC.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "cIEF Main peak",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_cIEF.csv",
      "path": "../data/aggregation/jain2024assessment_cIEF.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "HIC RT (min)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2018.1475871",
      "key_words": [
        "integrin alpha11",
        "Fv"
      ],
      "name": "jetha2019homology_RT.csv",
      "path": "../data/aggregation/jetha2019homology_RT.csv",
      "study": "Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies",
      "year": 2018,
      "license": "Attribution-NonCommercial-NoDerivatives 4.0 International",
      "size": 97
    },
    {
      "assay": "Heparin retention time (min)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1080/19420862.2019.1683432",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "kraft2019herapin_relrt.csv",
      "path": "../data/aggregation/kraft2019herapin_relrt.csv",
      "study": "Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis",
      "year": 2019,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 128
    },
    {
      "assay": "AC-SINS - Shift (nm)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_ACSINS.csv",
      "path": "../data/aggregation/shanehsazzadeh2023unlocking_ACSINS.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "Red-CGE - Purity (%)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_CGE.csv",
      "path": "../data/aggregation/shanehsazzadeh2023unlocking_CGE.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "HIC - RRT",
      "category": "aggregation",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_HICRRT.csv",
      "path": "../data/aggregation/shanehsazzadeh2023unlocking_HICRRT.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "NR-CGE - Main (%)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_NRCGE.csv",
      "path": "../data/aggregation/shanehsazzadeh2023unlocking_NRCGE.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "SEC - Main (%)",
      "category": "aggregation",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_SEC.csv",
      "path": "../data/aggregation/shanehsazzadeh2023unlocking_SEC.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "Predicted -log (Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-023-39022-2",
      "key_words": [
        "scFv",
        "SARS-CoV-2 peptide",
        "alphaseq"
      ],
      "name": "li2023machine_scFv-SARS-CoV-2_affinity1.csv.zip",
      "path": "../data/binding/li2023machine_scFv-SARS-CoV-2_affinity1.csv.zip",
      "study": "Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries",
      "year": 2023,
      "license": "Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License",
      "size": 1259701
    },
    {
      "assay": "Predicted -log (Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-023-39022-2",
      "key_words": [
        "scFv",
        "SARS-CoV-2 peptide",
        "alphaseq"
      ],
      "name": "li2023machine_scFv-SARS-CoV-2_affinity2.csv.zip",
      "path": "../data/binding/li2023machine_scFv-SARS-CoV-2_affinity2.csv.zip",
      "study": "Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries",
      "year": 2023,
      "license": "Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License",
      "size": 1903928
    },
    {
      "assay": "Kd [nM], IC50 [ug/mL]",
      "category": "binding",
      "doi": "https://doi.org/10.48550/arXiv.2506.17857",
      "key_words": [
        "Fv"
      ],
      "name": "AbRank_dataset.csv.zip",
      "path": "../data/binding/AbRank_dataset.csv.zip",
      "study": "AbRank: A Benchmark Dataset and Metric-Learning Framework for Antibody-Antigen Affinity Ranking",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 342357
    },
    {
      "assay": "Kd (flow) [M]",
      "category": "binding",
      "doi": "https://doi.org/10.7554/eLife.23156",
      "key_words": [
        "Fv"
      ],
      "name": "adams2017measuring_4420-fluorescein_kd-flow.csv",
      "path": "../data/binding/adams2017measuring_4420-fluorescein_kd-flow.csv",
      "study": "Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves",
      "year": 2017,
      "license": "Attribution 4.0 International",
      "size": 15
    },
    {
      "assay": "Kd (Tite-Seq) [M]",
      "category": "binding",
      "doi": "https://doi.org/10.7554/eLife.23156",
      "key_words": [
        "scFv",
        "fluorescein",
        "4-4-20"
      ],
      "name": "adams2017measuring_4420-fluorescein_kd-titeseq.csv",
      "path": "../data/binding/adams2017measuring_4420-fluorescein_kd-titeseq.csv",
      "study": "Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves",
      "year": 2017,
      "license": "Attribution 4.0 International",
      "size": 11052
    },
    {
      "assay": "bind/no bind",
      "category": "binding",
      "doi": "https://huggingface.co/datasets/COGNANO/AVIDa-hTNFa",
      "key_words": [
        "VHH",
        "human tumor necrosis factor alpha (TNFa)"
      ],
      "name": "cognano_AVIDa-hTNFa.csv",
      "path": "../data/binding/cognano_AVIDa-hTNFa.csv",
      "study": "none",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 5580
    },
    {
      "assay": "Predicted -log (Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41597-022-01779-4",
      "key_words": [
        "scFv",
        "SARS-CoV-2 peptide",
        "alphaseq"
      ],
      "name": "engelhart2022dataset_scFv-SARS-CoV-2_affinity.csv.zip",
      "path": "../data/binding/engelhart2022dataset_scFv-SARS-CoV-2_affinity.csv.zip",
      "study": "A dataset comprised of binding interactions for 104,972 antibodies against a SARS-CoV-2 peptide",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 352140
    },
    {
      "assay": "-log (KD [M] )",
      "category": "binding",
      "doi": "none",
      "key_words": [
        "none"
      ],
      "name": "garbinski2023_kd.csv",
      "path": "../data/binding/garbinski2023_kd.csv",
      "study": "none",
      "year": 2023,
      "license": "none",
      "size": 81
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "C143",
        "SARS-CoV-2-Beta-SP"
      ],
      "name": "hie2023efficient_CoV2Beta_C143_Kd.csv",
      "path": "../data/binding/hie2023efficient_CoV2Beta_C143_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 17
    },
    {
      "assay": "-log (Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "REGN10987",
        "SARS-CoV-Beta-SP"
      ],
      "name": "hie2023efficient_CoV2Beta_REGN10987_Kd.csv",
      "path": "../data/binding/hie2023efficient_CoV2Beta_REGN10987_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 14
    },
    {
      "assay": "-log (Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "S309",
        "SARS-CoV-2-WT-S6P"
      ],
      "name": "hie2023efficient_CoV2_S309_Kd.csv",
      "path": "../data/binding/hie2023efficient_CoV2_S309_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 20
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "REGN10987",
        "SARS-CoV-2-Omicron"
      ],
      "name": "hie2023efficient_CoV2omicron_REGN10987_Kd.csv",
      "path": "../data/binding/hie2023efficient_CoV2omicron_REGN10987_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 8
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "H1-Solomon",
        "MEDI-UCA"
      ],
      "name": "hie2023efficient_MEDIUCA_H1Solomon_Kd.csv",
      "path": "../data/binding/hie2023efficient_MEDIUCA_H1Solomon_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 21
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "H4-Hubei",
        "MEDI-UCA"
      ],
      "name": "hie2023efficient_MEDIUCA_H4Hubei_Kd.csv",
      "path": "../data/binding/hie2023efficient_MEDIUCA_H4Hubei_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 12
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "H4-Hubei",
        "MEDI"
      ],
      "name": "hie2023efficient_MEDI_H4Hubei_Kd.csv",
      "path": "../data/binding/hie2023efficient_MEDI_H4Hubei_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 16
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "H7-HK16",
        "MEDI"
      ],
      "name": "hie2023efficient_MEDI_H7HK16_Kd.csv",
      "path": "../data/binding/hie2023efficient_MEDI_H7HK16_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 17
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "Fv",
        "Ebola-Virus-GP",
        "mAb114"
      ],
      "name": "hie2023efficient_ebola_mab114_Kd.csv",
      "path": "../data/binding/hie2023efficient_ebola_mab114_Kd.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 21
    },
    {
      "assay": "-log (Kd [nM]) Fab",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_multikd_fab.csv",
      "path": "../data/binding/hutchinson2023enhancement_multikd_fab.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 15
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_multikd_igg.csv",
      "path": "../data/binding/hutchinson2023enhancement_multikd_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 15
    },
    {
      "assay": "-log (Kd [nM]) Fab",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_singlekd_fab.csv",
      "path": "../data/binding/hutchinson2023enhancement_singlekd_fab.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 22
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_singlekd_igg.csv",
      "path": "../data/binding/hutchinson2023enhancement_singlekd_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "-log (Kd [nM]) Fab",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_top200kd_fab.csv",
      "path": "../data/binding/hutchinson2023enhancement_top200kd_fab.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 50
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_top200kd_igg.csv",
      "path": "../data/binding/hutchinson2023enhancement_top200kd_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 182
    },
    {
      "assay": "-log (Kd [nM]) Fab",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_top27kd_fab.csv",
      "path": "../data/binding/hutchinson2023enhancement_top27kd_fab.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 28
    },
    {
      "assay": "-log (Kd [nM]) IgG",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "NIP228"
      ],
      "name": "hutchinson2023enhancement_top27kd_igg.csv",
      "path": "../data/binding/hutchinson2023enhancement_top27kd_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 27
    },
    {
      "assay": "Octet b-Hen Lysozyme Kd Monovalent (M)",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "Fv",
        "hen egg lysozyme (HEL)",
        "germline"
      ],
      "name": "jain2024assessment_Hen_Lys_kd.csv",
      "path": "../data/binding/jain2024assessment_Hen_Lys_kd.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 31
    },
    {
      "assay": "Octet IgG KD b-Mouse Lysozyme-Fc Avid (M)",
      "category": "binding",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "Fv",
        "b-Mouse Lysozyme-Fc",
        "germline"
      ],
      "name": "jain2024assessment_mouse_Ly_kd.csv",
      "path": "../data/binding/jain2024assessment_mouse_Ly_kd.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 2
    },
    {
      "assay": "bind/no bind",
      "category": "binding",
      "doi": "https://doi.org/10.1073/pnas.2412787122",
      "key_words": [
        "Fv",
        "SARS-CoV-2-Wuhan-hu-1",
        "CC12.1",
        "1-20"
      ],
      "name": "kirby2024retrospective_ab-SARSCoV2_binary_kd.csv",
      "path": "../data/binding/kirby2024retrospective_ab-SARSCoV2_binary_kd.csv",
      "study": "Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive",
      "year": 2025,
      "license": "none",
      "size": 1407
    },
    {
      "assay": "Kd [M]",
      "category": "binding",
      "doi": "https://doi.org/10.1073/pnas.2412787122",
      "key_words": [
        "Fv",
        "SARS-CoV-2-Wuhan-hu-1",
        "CC12.1",
        "1-20"
      ],
      "name": "kirby2024retrospective_ab-SARSCoV2_kd.csv",
      "path": "../data/binding/kirby2024retrospective_ab-SARSCoV2_kd.csv",
      "study": "Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive",
      "year": 2025,
      "license": "none",
      "size": 869
    },
    {
      "assay": "-log (Kd [M])",
      "category": "binding",
      "doi": "https://doi.org/10.1073/pnas.1613231114",
      "key_words": [
        "Fv",
        "G6.31",
        "VEGF"
      ],
      "name": "koenig2017mutational_kd_g6.csv",
      "path": "../data/binding/koenig2017mutational_kd_g6.csv",
      "study": "Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding",
      "year": 2017,
      "license": "none",
      "size": 4276
    },
    {
      "assay": "Cell Display  - EC50 (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "DCC",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_DCC_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_DCC_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "SPR kinetics - KD (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "DCC",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_DCC_spr.csv",
      "path": "../data/binding/kothiwal2025htp_DCC_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "Cell Display  - EC50 (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "DKK1",
        "VH1-69",
        "VK3-15",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_DKK_1.00_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_DKK_1.00_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 18
    },
    {
      "assay": "SPR kinetics - KD (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "DKK1",
        "VH1-69",
        "VK3-15",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_DKK_1.00_spr.csv",
      "path": "../data/binding/kothiwal2025htp_DKK_1.00_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 20
    },
    {
      "assay": "Cell Display  - EC50 (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "IL23R",
        "VH1-69",
        "VK3-15",
        "VK3-20",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_IL23R_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_IL23R_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 56
    },
    {
      "assay": "SPR kinetics - KD (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Fv",
        "IL23R",
        "VH1-69",
        "VK3-15",
        "VK3-20",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_IL23R_spr.csv",
      "path": "../data/binding/kothiwal2025htp_IL23R_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 70
    },
    {
      "assay": "Cell Display  - EC50 (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "LOX1",
        "VH1-69",
        "VK4-1",
        "VK3-15",
        "VK1-39"
      ],
      "name": "kothiwal2025htp_LOX1_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_LOX1_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 52
    },
    {
      "assay": "SPR kinetics - KD (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "LOX1",
        "VH1-69",
        "VK4-1",
        "VK3-15",
        "VK1-39"
      ],
      "name": "kothiwal2025htp_LOX1_spr.csv",
      "path": "../data/binding/kothiwal2025htp_LOX1_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 53
    },
    {
      "assay": "Cell Display  - EC50 (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "PDL1",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_PDL1_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_PDL1_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 34
    },
    {
      "assay": "SPR kinetics - KD (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "PDL1",
        "VH1-69",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_PDL1_spr.csv",
      "path": "../data/binding/kothiwal2025htp_PDL1_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 29
    },
    {
      "assay": "Cell Display  - EC50 (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "PDL2",
        "VH1-69",
        "VK1-39",
        "VK3-15"
      ],
      "name": "kothiwal2025htp_PDL2_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_PDL2_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "SPR kinetics - KD (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "PDL2",
        "VH1-69",
        "VK1-39",
        "VK3-15"
      ],
      "name": "kothiwal2025htp_PDL2_spr.csv",
      "path": "../data/binding/kothiwal2025htp_PDL2_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "Cell Display  - EC50 (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "ROBO1",
        "VH1-69",
        "VK4-1",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_ROBO1_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_ROBO1_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 45
    },
    {
      "assay": "SPR kinetics - KD (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "ROBO1",
        "VH1-69",
        "VK4-1",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_ROBO1_spr.csv",
      "path": "../data/binding/kothiwal2025htp_ROBO1_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 39
    },
    {
      "assay": "Cell Display  - EC50 (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "ROBO2N",
        "VH1-69",
        "VK3-15",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_ROBO2N_hROBO2N_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_ROBO2N_hROBO2N_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 22
    },
    {
      "assay": "SPR kinetics - KD (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "ROBO2N",
        "VH1-69",
        "VK3-15",
        "VK4-1"
      ],
      "name": "kothiwal2025htp_ROBO2N_hROBO2N_spr.csv",
      "path": "../data/binding/kothiwal2025htp_ROBO2N_hROBO2N_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 22
    },
    {
      "assay": "Cell Display  - EC50 (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Syncytin2",
        "VH1-69",
        "VK4-1",
        "VK1-39",
        "VK3-15",
        "VH1-39",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_Syncytin2_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_Syncytin2_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 48
    },
    {
      "assay": "SPR kinetics - KD (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "Syncytin2",
        "VH1-69",
        "VK4-1",
        "VK1-39",
        "VK3-15",
        "VH1-39",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_Syncytin2_spr.csv",
      "path": "../data/binding/kothiwal2025htp_Syncytin2_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 51
    },
    {
      "assay": "Cell Display  - EC50 (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "TIGIT",
        "VH1-69",
        "VK4-1",
        "VK1-39",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_TIGIT_ec50.csv",
      "path": "../data/binding/kothiwal2025htp_TIGIT_ec50.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 24
    },
    {
      "assay": "SPR kinetics - KD (nM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2025.05.15.650607",
      "key_words": [
        "TIGIT",
        "VH1-69",
        "VK4-1",
        "VK1-39",
        "VH1-69"
      ],
      "name": "kothiwal2025htp_TIGIT_spr.csv",
      "path": "../data/binding/kothiwal2025htp_TIGIT_spr.csv",
      "study": "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "year": 2025,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 22
    },
    {
      "assay": "ANT binding",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-022-31457-3",
      "key_words": [
        "Fv",
        "ANT",
        "emibetuzumab"
      ],
      "name": "makowksi2022cooptimization_iso_ant.csv",
      "path": "../data/binding/makowksi2022cooptimization_iso_ant.csv",
      "study": "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 126
    },
    {
      "assay": "ANT binding",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-022-31457-3",
      "key_words": [
        "Fv",
        "ANT",
        "emibetuzumab"
      ],
      "name": "makowski2022cooptimization_igg_ant.csv",
      "path": "../data/binding/makowski2022cooptimization_igg_ant.csv",
      "study": "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 96
    },
    {
      "assay": "OVA binding",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-022-31457-3",
      "key_words": [
        "Fv",
        "OVA",
        "emibetuzumab"
      ],
      "name": "makowski2022cooptimization_igg_ova.csv",
      "path": "../data/binding/makowski2022cooptimization_igg_ova.csv",
      "study": "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 96
    },
    {
      "assay": "OVA binding",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-022-31457-3",
      "key_words": [
        "Fv",
        "OVA",
        "emibetuzumab"
      ],
      "name": "makowski2022cooptimization_iso_ova.csv",
      "path": "../data/binding/makowski2022cooptimization_iso_ova.csv",
      "study": "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 126
    },
    {
      "assay": "bind/no bind",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-024-48072-z",
      "key_words": [
        "Fv",
        "H1HA"
      ],
      "name": "peterson2024integrated_ab_H1HA_binary.csv",
      "path": "../data/binding/peterson2024integrated_ab_H1HA_binary.csv",
      "study": "An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries",
      "year": 2024,
      "license": "Attribution 4.0 International",
      "size": 1071
    },
    {
      "assay": "MAGMA-Seq Kd [M]",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-024-48072-z",
      "key_words": [
        "Fv",
        "H1HA"
      ],
      "name": "peterson2024integrated_ab_H1HA_kd.csv",
      "path": "../data/binding/peterson2024integrated_ab_H1HA_kd.csv",
      "study": "An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries",
      "year": 2024,
      "license": "Attribution 4.0 International",
      "size": 1040
    },
    {
      "assay": "-log( Kd [nM]) Fab",
      "category": "binding",
      "doi": "https://doi.org/10.7554/elife.71393",
      "key_words": [
        "Fv",
        "cr6261",
        "H1"
      ],
      "name": "phillips2021binding_cr6261_h1_kd.csv",
      "path": "../data/binding/phillips2021binding_cr6261_h1_kd.csv",
      "study": "Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies",
      "year": 2021,
      "license": "Attribution 4.0 International",
      "size": 953
    },
    {
      "assay": "-log( Kd [nM]) Fab",
      "category": "binding",
      "doi": "https://doi.org/10.7554/elife.71393",
      "key_words": [
        "Fv",
        "cr6261",
        "H9"
      ],
      "name": "phillips2021binding_cr6261_h9_kd.csv",
      "path": "../data/binding/phillips2021binding_cr6261_h9_kd.csv",
      "study": "Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies",
      "year": 2021,
      "license": "Attribution 4.0 International",
      "size": 921
    },
    {
      "assay": "-log( Kd [nM]) Fab",
      "category": "binding",
      "doi": "https://doi.org/10.7554/elife.71393",
      "key_words": [
        "Fv",
        "cr9114",
        "H1"
      ],
      "name": "phillips2021binding_cr9114_h1_kd.csv",
      "path": "../data/binding/phillips2021binding_cr9114_h1_kd.csv",
      "study": "Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies",
      "year": 2021,
      "license": "Attribution 4.0 International",
      "size": 32393
    },
    {
      "assay": "-log( Kd [nM]) Fab",
      "category": "binding",
      "doi": "https://doi.org/10.7554/elife.71393",
      "key_words": [
        "Fv",
        "cr9114",
        "H3"
      ],
      "name": "phillips2021binding_cr9114_h3_kd.csv",
      "path": "../data/binding/phillips2021binding_cr9114_h3_kd.csv",
      "study": "Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies",
      "year": 2021,
      "license": "Attribution 4.0 International",
      "size": 32768
    },
    {
      "assay": "IC50 (ng/ml)",
      "category": "binding",
      "doi": "https://doi.org/10.1093/bioinformatics/btac439",
      "key_words": [
        "Fv",
        "CoV"
      ],
      "name": "rawat2022abcov_ic50.csv",
      "path": "../data/binding/rawat2022abcov_ic50.csv",
      "study": "Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus-related antibodies",
      "year": 2022,
      "license": "none",
      "size": 427
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1093/bioinformatics/btac439",
      "key_words": [
        "Fv",
        "CoV"
      ],
      "name": "rawat2022abcov_kd.csv",
      "path": "../data/binding/rawat2022abcov_kd.csv",
      "study": "Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus-related antibodies",
      "year": 2022,
      "license": "none",
      "size": 141
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Adalimumab",
        "Fv"
      ],
      "name": "rosace2023automated_kd_adalimumab.csv",
      "path": "../data/binding/rosace2023automated_kd_adalimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 14
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Golimumab",
        "Fv"
      ],
      "name": "rosace2023automated_kd_golimumab.csv",
      "path": "../data/binding/rosace2023automated_kd_golimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 5
    },
    {
      "assay": "ADCC EC50 (pM)",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_adcc_ec50.csv",
      "path": "../data/binding/shanehsazzadeh2023unlocking_adcc_ec50.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "-log( Kd [nM]) Fab",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv",
        "hHER2"
      ],
      "name": "shanehsazzadeh2023unlocking_kd_hher2_fab.csv",
      "path": "../data/binding/shanehsazzadeh2023unlocking_kd_hher2_fab.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "-log( Kd [nM]) mAb",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv",
        "hHER2"
      ],
      "name": "shanehsazzadeh2023unlocking_kd_hher2_mab.csv",
      "path": "../data/binding/shanehsazzadeh2023unlocking_kd_hher2_mab.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_zerokd_trastuzumab.csv",
      "path": "../data/binding/shanehsazzadeh2023unlocking_zerokd_trastuzumab.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 422
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Afasevikumab",
        "IL17A"
      ],
      "name": "shanehsazzadeh2024igdesign_Afasevikumab-IL17A_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Afasevikumab-IL17A_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 13
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Bimagrumab",
        "ACVR2B"
      ],
      "name": "shanehsazzadeh2024igdesign_Bimagrumab-ACVR2B_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Bimagrumab-ACVR2B_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 24
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Eculizumab",
        "C5"
      ],
      "name": "shanehsazzadeh2024igdesign_Eculizumab-C5_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Eculizumab-C5_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 34
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Osocimab",
        "FXI"
      ],
      "name": "shanehsazzadeh2024igdesign_Osocimab-FXI_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Osocimab-FXI_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 47
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Spesolimab",
        "IL36R"
      ],
      "name": "shanehsazzadeh2024igdesign_Spesolimab-IL36R_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Spesolimab-IL36R_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 40
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Tezepelumab",
        "TSLP"
      ],
      "name": "shanehsazzadeh2024igdesign_Tezepelumab-TSLP_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Tezepelumab-TSLP_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 127
    },
    {
      "assay": "-log( Kd [nM])",
      "category": "binding",
      "doi": "https://doi.org/10.1101/2023.12.08.570889",
      "key_words": [
        "Utomilumab",
        "TNFRSF9"
      ],
      "name": "shanehsazzadeh2024igdesign_Utomilumab-TNFRSF9_kd.csv",
      "path": "../data/binding/shanehsazzadeh2024igdesign_Utomilumab-TNFRSF9_kd.csv",
      "study": "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "year": 2024,
      "license": "MIT License",
      "size": 36
    },
    {
      "assay": "Avg Neutralization IC50 (ng/microL)",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "Ly1404",
        "BQ.1.1"
      ],
      "name": "shanker2024unsupervised_Ly1404-BQ.1.1_IC50.csv",
      "path": "../data/binding/shanker2024unsupervised_Ly1404-BQ.1.1_IC50.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 50
    },
    {
      "assay": "Kd [M]",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "Ly1404",
        "BQ.1.1"
      ],
      "name": "shanker2024unsupervised_Ly1404-BQ.1.1_Kd.csv",
      "path": "../data/binding/shanker2024unsupervised_Ly1404-BQ.1.1_Kd.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 36
    },
    {
      "assay": "Avg Neutralization IC50 (ng/microL)",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "Ly1404",
        "SARS-CoV-2-Wuhan"
      ],
      "name": "shanker2024unsupervised_Ly1404_Wuhan_IC50.csv",
      "path": "../data/binding/shanker2024unsupervised_Ly1404_Wuhan_IC50.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 33
    },
    {
      "assay": "Avg Neutralization IC50 (ng/microL)",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "SA58",
        "BA.1"
      ],
      "name": "shanker2024unsupervised_SA58-BA.1_IC50.csv",
      "path": "../data/binding/shanker2024unsupervised_SA58-BA.1_IC50.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 19
    },
    {
      "assay": "Avg Neutralization IC50 (ng/microL)",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "SA58",
        "BQ.1.1"
      ],
      "name": "shanker2024unsupervised_SA58-BQ.1.1_IC50.csv",
      "path": "../data/binding/shanker2024unsupervised_SA58-BQ.1.1_IC50.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 49
    },
    {
      "assay": "Kd [M]",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "SA58",
        "BQ.1.1"
      ],
      "name": "shanker2024unsupervised_SA58-BQ.1.1_Kd.csv",
      "path": "../data/binding/shanker2024unsupervised_SA58-BQ.1.1_Kd.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 7
    },
    {
      "assay": "Kd [M]",
      "category": "binding",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "SA58",
        "XBB.1.5"
      ],
      "name": "shanker2024unsupervised_SA58-XBB.1.5_Kd.csv",
      "path": "../data/binding/shanker2024unsupervised_SA58-XBB.1.5_Kd.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 30
    },
    {
      "assay": "bind/no bind",
      "category": "binding",
      "doi": "https://doi.org/10.48550/arXiv.2306.03329",
      "key_words": [
        "VHH",
        "hIL6"
      ],
      "name": "tsuruta2024avida-hIL6_binary.csv.zip",
      "path": "../data/binding/tsuruta2024avida-hIL6_binary.csv.zip",
      "study": "AVIDa-hIL6: A Large-Scale VHH Dataset Produced from an Immunized Alpaca for Predicting Antigen-Antibody Interactions",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 573892
    },
    {
      "assay": "bind/no bind",
      "category": "binding",
      "doi": "https://doi.org/10.48550/arXiv.2405.18749",
      "key_words": [
        "VHH",
        "SARS-CoV-2"
      ],
      "name": "tsuruta2024sarscov2_binary.csv.zip",
      "path": "../data/binding/tsuruta2024sarscov2_binary.csv.zip",
      "study": "A SARS-CoV-2 Interaction Dataset and VHH Sequence Corpus for Antibody Language Models",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 77004
    },
    {
      "assay": "-log( Kd [M])",
      "category": "binding",
      "doi": "https://doi.org/10.1371/journal.pcbi.1007207",
      "key_words": [
        "d44"
      ],
      "name": "warszawski2019_d44_Kd.csv",
      "path": "../data/binding/warszawski2019_d44_Kd.csv",
      "study": "Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces",
      "year": 2019,
      "license": "Attribution 4.0 International",
      "size": 2049
    },
    {
      "assay": "-log( Kd [M])",
      "category": "binding",
      "doi": "https://doi.org/10.1073/pnas.0603282103",
      "key_words": [
        "4-4-20",
        "fluorescein"
      ],
      "name": "zimmerman2020antibody_4420_kd.csv",
      "path": "../data/binding/zimmerman2020antibody_4420_kd.csv",
      "study": "Antibody evolution constrains conformational heterogeneity by tailoring protein dynamics",
      "year": 2006,
      "license": "none",
      "size": 21
    },
    {
      "assay": "Expression [ER]",
      "category": "expression",
      "doi": "https://doi.org/10.7554/eLife.23156",
      "key_words": [
        "4-4-20",
        "fluorescein",
        "Fab"
      ],
      "name": "adams2017measuring_4420-fluorescein_exp_er.csv",
      "path": "../data/expression/adams2017measuring_4420-fluorescein_exp_er.csv",
      "study": "Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves",
      "year": 2017,
      "license": "Attribution 4.0 International",
      "size": 10970
    },
    {
      "assay": "Expression (microg/mL)",
      "category": "expression",
      "doi": "none",
      "key_words": [
        "none"
      ],
      "name": "garbinski2023_exp.csv",
      "path": "../data/expression/garbinski2023_exp.csv",
      "study": "none",
      "year": 2023,
      "license": "none",
      "size": 94
    },
    {
      "assay": "HEK Titer (mg/L)",
      "category": "expression",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_HEK.csv",
      "path": "../data/expression/jain2017biophysical_HEK.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "Expression [ER]",
      "category": "expression",
      "doi": "https://doi.org/10.1073/pnas.1613231114",
      "key_words": [
        "G6.31",
        "VEGF"
      ],
      "name": "koenig2017mutational_er_g6.csv",
      "path": "../data/expression/koenig2017mutational_er_g6.csv",
      "study": "Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding",
      "year": 2017,
      "license": "none",
      "size": 4276
    },
    {
      "assay": "%ADA response",
      "category": "immunogenicity",
      "doi": "https://doi.org/10.1093/bioinformatics/btab434",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "marks2021humanization_immunogenicity.csv",
      "path": "../data/immunogenicity/marks2021humanization_immunogenicity.csv",
      "study": "Humanization of antibodies using a machine learning approach on large-scale repertoire data",
      "year": 2021,
      "license": "Attribution 4.0 International",
      "size": 217
    },
    {
      "assay": "FcRn.Rel.RT.3",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_FcRnRelRT3.csv",
      "path": "../data/pharmacokinetics/jain2023identifying_FcRnRelRT3.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 132
    },
    {
      "assay": "Hep.RT.3",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_HEPRT3.csv",
      "path": "../data/pharmacokinetics/jain2023identifying_HEPRT3.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 130
    },
    {
      "assay": "FcRn Cellular Recycling (ng/mL)",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2024assessment_FcRn.csv",
      "path": "../data/pharmacokinetics/jain2024assessment_FcRn.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "Tg32 Clearance (ml/h/kg)",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2024assessment_tg32_clearance.csv",
      "path": "../data/pharmacokinetics/jain2024assessment_tg32_clearance.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "Tg32 half-life (h)",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2024assessment_tg32_halflife.csv",
      "path": "../data/pharmacokinetics/jain2024assessment_tg32_halflife.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "pI",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1038/s41467-022-31457-3",
      "key_words": [
        "emibetuzumab"
      ],
      "name": "makowski2022cooptimization_pI.csv",
      "path": "../data/pharmacokinetics/makowski2022cooptimization_pI.csv",
      "study": "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 126
    },
    {
      "assay": "FcRn chromatography - Peak width (min)",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_FcRnPeak.csv",
      "path": "../data/pharmacokinetics/shanehsazzadeh2023unlocking_FcRnPeak.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "FcRn chromatography - RRT",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_FcRnRRT.csv",
      "path": "../data/pharmacokinetics/shanehsazzadeh2023unlocking_FcRnRRT.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "FcRn chromatography - Retention time (min)",
      "category": "pharmacokinetics",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_FcRnRT.csv",
      "path": "../data/pharmacokinetics/shanehsazzadeh2023unlocking_FcRnRT.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "BVP ELISA",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_BVPELISA.csv",
      "path": "../data/polyreactivity/jain2017biophysical_BVPELISA.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "CIC Retention Time (Min)",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_CICRT.csv",
      "path": "../data/polyreactivity/jain2017biophysical_CICRT.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "ELISA",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_ELISA.csv",
      "path": "../data/polyreactivity/jain2017biophysical_ELISA.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "Poly-Specficity Reagent (PSR) SMP Score (0-1)",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_PSR.csv",
      "path": "../data/polyreactivity/jain2017biophysical_PSR.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "SMAC Retention Time (Min)a",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_SMACRT.csv",
      "path": "../data/polyreactivity/jain2017biophysical_SMACRT.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "DNP",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_DNP.csv",
      "path": "../data/polyreactivity/jain2023identifying_DNP.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 112
    },
    {
      "assay": "FA.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_FA2.csv",
      "path": "../data/polyreactivity/jain2023identifying_FA2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 113
    },
    {
      "assay": "Fe.C3.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_FVC32.csv",
      "path": "../data/polyreactivity/jain2023identifying_FVC32.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 115
    },
    {
      "assay": "Fe.FVIII.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_FvFVIII2.csv",
      "path": "../data/polyreactivity/jain2023identifying_FvFVIII2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 115
    },
    {
      "assay": "Fe.LysM.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_FvLysM2.csv",
      "path": "../data/polyreactivity/jain2023identifying_FvLysM2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 115
    },
    {
      "assay": "Heme.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_Heme2.csv",
      "path": "../data/polyreactivity/jain2023identifying_Heme2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 113
    },
    {
      "assay": "Heme.C3.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_HemeC32.csv",
      "path": "../data/polyreactivity/jain2023identifying_HemeC32.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 113
    },
    {
      "assay": "Heme.FViii.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_HemeFVIII2.csv",
      "path": "../data/polyreactivity/jain2023identifying_HemeFVIII2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 113
    },
    {
      "assay": "Heme.LysM.2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2023.2200540",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2023identifying_HemeLysM2.csv",
      "path": "../data/polyreactivity/jain2023identifying_HemeLysM2.csv",
      "study": "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "year": 2023,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 113
    },
    {
      "assay": "Herapin Column Rel RT",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_Herapin_RT.csv",
      "path": "../data/polyreactivity/jain2024assessment_Herapin_RT.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "PSR",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_PSR.csv",
      "path": "../data/polyreactivity/jain2024assessment_PSR.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "CIC RT (min) rep1",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Adalimumab",
        "Fv"
      ],
      "name": "rosace2023automated_CICRT1_adalimumab.csv",
      "path": "../data/polyreactivity/rosace2023automated_CICRT1_adalimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 14
    },
    {
      "assay": "CIC RT (min) rep1",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Golimumab",
        "Fv"
      ],
      "name": "rosace2023automated_CICRT1_golimumab.csv",
      "path": "../data/polyreactivity/rosace2023automated_CICRT1_golimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 5
    },
    {
      "assay": "CIC RT (min) rep2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Adalimumab",
        "Fv"
      ],
      "name": "rosace2023automated_CICRT2_adalimumab.csv",
      "path": "../data/polyreactivity/rosace2023automated_CICRT2_adalimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 14
    },
    {
      "assay": "CIC RT (min) rep2",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Golimumab",
        "Fv"
      ],
      "name": "rosace2023automated_CICRT2_golimumab.csv",
      "path": "../data/polyreactivity/rosace2023automated_CICRT2_golimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 5
    },
    {
      "assay": "cELISA EC50 (pM)",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_elisa_ec50.csv",
      "path": "../data/polyreactivity/shanehsazzadeh2023unlocking_elisa_ec50.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "Polyspecificity - Anti-DNA (AU)",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_polyspecificity.csv",
      "path": "../data/polyreactivity/shanehsazzadeh2023unlocking_polyspecificity.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "APC-MFI",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "Elotuzumab",
        "Ixekuzimab",
        "Fv"
      ],
      "name": "shanker2024unsupervised_APC-MFI_Elotuzumab-Ixekuzimab.csv",
      "path": "../data/polyreactivity/shanker2024unsupervised_APC-MFI_Elotuzumab-Ixekuzimab.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 6
    },
    {
      "assay": "APC-MFI",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "Ly1404",
        "Fv"
      ],
      "name": "shanker2024unsupervised_APC-MFI_Ly1404.csv",
      "path": "../data/polyreactivity/shanker2024unsupervised_APC-MFI_Ly1404.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 18
    },
    {
      "assay": "ACP-MFI",
      "category": "polyreactivity",
      "doi": "https://doi.org/10.1126/science.adk8946",
      "key_words": [
        "SA58"
      ],
      "name": "shanker2024unsupervised_APC-MFI_SA58.csv",
      "path": "../data/polyreactivity/shanker2024unsupervised_APC-MFI_SA58.csv",
      "study": "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "year": 2024,
      "license": "MIT License",
      "size": 15
    },
    {
      "assay": "Tm1 (nanoDSF)",
      "category": "thermostability",
      "doi": "none",
      "key_words": [
        "none"
      ],
      "name": "garbinski2023_tm1.csv",
      "path": "../data/thermostability/garbinski2023_tm1.csv",
      "study": "none",
      "year": 2023,
      "license": "none",
      "size": 86
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "C143"
      ],
      "name": "hie2023efficient_C143_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_C143_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 2
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "MEDIUCA"
      ],
      "name": "hie2023efficient_MEDIUCA_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_MEDIUCA_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 6
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "MEDI"
      ],
      "name": "hie2023efficient_MEDI_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_MEDI_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 2
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "REGN10987"
      ],
      "name": "hie2023efficient_REGN10987_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_REGN10987_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 8
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "S309"
      ],
      "name": "hie2023efficient_S309_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_S309_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 10
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "mAb114UCA"
      ],
      "name": "hie2023efficient_mAb114UCA_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_mAb114UCA_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 2
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41587-023-01763-2",
      "key_words": [
        "mAb114"
      ],
      "name": "hie2023efficient_mAb114_Tm.csv",
      "path": "../data/thermostability/hie2023efficient_mAb114_Tm.csv",
      "study": "Efficient evolution of human antibodies from general protein language models",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 7
    },
    {
      "assay": "Tm1 (degreeC) IgG",
      "category": "thermostability",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv"
      ],
      "name": "hutchinson2023enhancement_multitm1_igg.csv",
      "path": "../data/thermostability/hutchinson2023enhancement_multitm1_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 15
    },
    {
      "assay": "Tm1 (degreeC) IgG",
      "category": "thermostability",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv"
      ],
      "name": "hutchinson2023enhancement_singletm1_igg.csv",
      "path": "../data/thermostability/hutchinson2023enhancement_singletm1_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 23
    },
    {
      "assay": "Tm1 (degreeC) IgG",
      "category": "thermostability",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv"
      ],
      "name": "hutchinson2023enhancement_top200tm1_igg.csv",
      "path": "../data/thermostability/hutchinson2023enhancement_top200tm1_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 192
    },
    {
      "assay": "Tm1 (degreeC) IgG",
      "category": "thermostability",
      "doi": "https://doi.org/10.1080/19420862.2024.2362775",
      "key_words": [
        "Fv"
      ],
      "name": "hutchinson2023enhancement_top27tm1_igg.csv",
      "path": "../data/thermostability/hutchinson2023enhancement_top27tm1_igg.csv",
      "study": "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 28
    },
    {
      "assay": "Fab Tm by DSF (degreeC)",
      "category": "thermostability",
      "doi": "https://doi.org/10.1073/pnas.1616408114",
      "key_words": [
        "clinical stage therapeutic",
        "Fv"
      ],
      "name": "jain2017biophysical_Tm.csv",
      "path": "../data/thermostability/jain2017biophysical_Tm.csv",
      "study": "Biophysical properties of the clinical-stage antibody landscape",
      "year": 2017,
      "license": "none",
      "size": 137
    },
    {
      "assay": "Fab Tm by DSF (degreeC)",
      "category": "thermostability",
      "doi": "https://doi.org/10.1080/19420862.2024.2384104",
      "key_words": [
        "germline",
        "Fv"
      ],
      "name": "jain2024assessment_Tm.csv",
      "path": "../data/thermostability/jain2024assessment_Tm.csv",
      "study": "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "year": 2024,
      "license": "Attribution-NonCommercial 4.0 International",
      "size": 43
    },
    {
      "assay": "Tm (C) rep1",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Adalimumab",
        "Fv"
      ],
      "name": "rosace2023automated_tm1_adalimumab.csv",
      "path": "../data/thermostability/rosace2023automated_tm1_adalimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 14
    },
    {
      "assay": "Tm (C) rep1",
      "category": "thermostability",
      "doi": "https://doi.org/10.1038/s41467-023-37668-6",
      "key_words": [
        "Golimumab",
        "Fv"
      ],
      "name": "rosace2023automated_tm1_golimumab.csv",
      "path": "../data/thermostability/rosace2023automated_tm1_golimumab.csv",
      "study": "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "year": 2022,
      "license": "Attribution 4.0 International",
      "size": 5
    },
    {
      "assay": "DLS - Cumulant PDI",
      "category": "thermostability",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_DLS.csv",
      "path": "../data/thermostability/shanehsazzadeh2023unlocking_DLS.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "DSF - IP #1 (oC)",
      "category": "thermostability",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_DSF1.csv",
      "path": "../data/thermostability/shanehsazzadeh2023unlocking_DSF1.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "DSF - IP #2 (oC)",
      "category": "thermostability",
      "doi": "https://doi.org/10.1101/2023.01.08.523187",
      "key_words": [
        "Trastuzumab",
        "Fv"
      ],
      "name": "shanehsazzadeh2023unlocking_DSF2.csv",
      "path": "../data/thermostability/shanehsazzadeh2023unlocking_DSF2.csv",
      "study": "Unlocking de novo antibody design with generative artificial intelligence",
      "year": 2024,
      "license": "Clear BSD",
      "size": 13
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1371/journal.pone.0181490",
      "key_words": [
        "sdAb"
      ],
      "name": "sulea2019assisted_sdAb_tm.csv",
      "path": "../data/thermostability/sulea2019assisted_sdAb_tm.csv",
      "study": "Assisted Design of Antibody and Protein Therapeutics (ADAPT)",
      "year": 2019,
      "license": "Attribution 4.0 International",
      "size": 33
    },
    {
      "assay": "Tm",
      "category": "thermostability",
      "doi": "https://doi.org/10.1093/database/baad021",
      "key_words": [
        "Nanobody"
      ],
      "name": "tresanco2023nbthermo_tm.csv",
      "path": "../data/thermostability/tresanco2023nbthermo_tm.csv",
      "study": "NbThermo: a new thermostability database for nanobodies ",
      "year": 2023,
      "license": "Attribution 4.0 International",
      "size": 673
    }
  ],
  "keys": {
    "assay": [
      "HIC Retention Time (Min)a",
      "Affinity-Capture Self-Interaction Nanoparticle Spectroscopy (AC-SINS) delta lambda max (nm) Average",
      "CSI-BLI Delta Response (nm)",
      "Slope for Accelerated Stability",
      "SGAC-SINS AS100 ((NH4)2SO4 mM)",
      "AC-SINS delta lambda max (nm)",
      "CIC Column K",
      "CS-SINS (ave)",
      "Fab.pI",
      "HIC RT (min)",
      "SEC % Monomer",
      "cIEF Main peak",
      "Heparin retention time (min)",
      "AC-SINS - Shift (nm)",
      "Red-CGE - Purity (%)",
      "HIC - RRT",
      "NR-CGE - Main (%)",
      "SEC - Main (%)",
      "Predicted -log (Kd [nM])",
      "Kd [nM], IC50 [ug/mL]",
      "Kd (flow) [M]",
      "Kd (Tite-Seq) [M]",
      "bind/no bind",
      "-log (KD [M] )",
      "-log (Kd [nM]) IgG",
      "-log (Kd [nM])",
      "-log (Kd [nM]) Fab",
      "Octet b-Hen Lysozyme Kd Monovalent (M)",
      "Octet IgG KD b-Mouse Lysozyme-Fc Avid (M)",
      "Kd [M]",
      "-log (Kd [M])",
      "Cell Display  - EC50 (nM)",
      "SPR kinetics - KD (nM)",
      "ANT binding",
      "OVA binding",
      "MAGMA-Seq Kd [M]",
      "-log( Kd [nM]) Fab",
      "IC50 (ng/ml)",
      "-log( Kd [nM])",
      "ADCC EC50 (pM)",
      "-log( Kd [nM]) mAb",
      "Avg Neutralization IC50 (ng/microL)",
      "-log( Kd [M])",
      "Expression [ER]",
      "Expression (microg/mL)",
      "HEK Titer (mg/L)",
      "%ADA response",
      "FcRn.Rel.RT.3",
      "Hep.RT.3",
      "FcRn Cellular Recycling (ng/mL)",
      "Tg32 Clearance (ml/h/kg)",
      "Tg32 half-life (h)",
      "pI",
      "FcRn chromatography - Peak width (min)",
      "FcRn chromatography - RRT",
      "FcRn chromatography - Retention time (min)",
      "BVP ELISA",
      "CIC Retention Time (Min)",
      "ELISA",
      "Poly-Specficity Reagent (PSR) SMP Score (0-1)",
      "SMAC Retention Time (Min)a",
      "DNP",
      "FA.2",
      "Fe.C3.2",
      "Fe.FVIII.2",
      "Fe.LysM.2",
      "Heme.2",
      "Heme.C3.2",
      "Heme.FViii.2",
      "Heme.LysM.2",
      "Herapin Column Rel RT",
      "PSR",
      "CIC RT (min) rep1",
      "CIC RT (min) rep2",
      "cELISA EC50 (pM)",
      "Polyspecificity - Anti-DNA (AU)",
      "APC-MFI",
      "ACP-MFI",
      "Tm1 (nanoDSF)",
      "Tm",
      "Tm1 (degreeC) IgG",
      "Fab Tm by DSF (degreeC)",
      "Tm (C) rep1",
      "DLS - Cumulant PDI",
      "DSF - IP #1 (oC)",
      "DSF - IP #2 (oC)"
    ],
    "category": [
      "aggregation",
      "binding",
      "expression",
      "immunogenicity",
      "pharmacokinetics",
      "polyreactivity",
      "thermostability"
    ],
    "doi": [
      "https://doi.org/10.1073/pnas.1616408114",
      "https://doi.org/10.1080/19420862.2024.2384104",
      "https://doi.org/10.1080/19420862.2018.1475871",
      "https://doi.org/10.1080/19420862.2019.1683432",
      "https://doi.org/10.1101/2023.01.08.523187",
      "https://doi.org/10.1038/s41467-023-39022-2",
      "https://doi.org/10.48550/arXiv.2506.17857",
      "https://doi.org/10.7554/eLife.23156",
      "https://huggingface.co/datasets/COGNANO/AVIDa-hTNFa",
      "https://doi.org/10.1038/s41597-022-01779-4",
      "none",
      "https://doi.org/10.1038/s41587-023-01763-2",
      "https://doi.org/10.1080/19420862.2024.2362775",
      "https://doi.org/10.1073/pnas.2412787122",
      "https://doi.org/10.1073/pnas.1613231114",
      "https://doi.org/10.1101/2025.05.15.650607",
      "https://doi.org/10.1038/s41467-022-31457-3",
      "https://doi.org/10.1038/s41467-024-48072-z",
      "https://doi.org/10.7554/elife.71393",
      "https://doi.org/10.1093/bioinformatics/btac439",
      "https://doi.org/10.1038/s41467-023-37668-6",
      "https://doi.org/10.1101/2023.12.08.570889",
      "https://doi.org/10.1126/science.adk8946",
      "https://doi.org/10.48550/arXiv.2306.03329",
      "https://doi.org/10.48550/arXiv.2405.18749",
      "https://doi.org/10.1371/journal.pcbi.1007207",
      "https://doi.org/10.1073/pnas.0603282103",
      "https://doi.org/10.1093/bioinformatics/btab434",
      "https://doi.org/10.1080/19420862.2023.2200540",
      "https://doi.org/10.1371/journal.pone.0181490",
      "https://doi.org/10.1093/database/baad021"
    ],
    "key_words": [
      "",
      "Adalimumab",
      "human tumor necrosis factor alpha (TNFa)",
      "G6.31",
      "DCC",
      "Spesolimab",
      "ANT",
      "Nanobody",
      "SARS-CoV-2-Omicron",
      "Fab",
      "CC12.1",
      "Elotuzumab",
      "C5",
      "TSLP",
      "VH1-39",
      "Tezepelumab",
      "CoV",
      "NIP228",
      "MEDIUCA",
      "IL17A",
      "LOX1",
      "SARS-CoV-2-Beta-SP",
      "SARS-CoV-Beta-SP",
      "trastuzumab",
      "hIL6",
      "TIGIT",
      "VK4-1",
      "d44",
      "ROBO2N",
      "C143",
      "sdAb",
      "H3",
      "cr9114",
      "b-Mouse Lysozyme-Fc",
      "BQ.1.1",
      "Utomilumab",
      "H4-Hubei",
      "alphaseq",
      "VK3-20",
      "VK3-15",
      "IL23R",
      "OVA",
      "SARS-CoV-2",
      "TNFRSF9",
      "BA.1",
      "hen egg lysozyme (HEL)",
      "mAb114",
      "ACVR2B",
      "Ly1404",
      "SARS-CoV-2-Wuhan-hu-1",
      "VEGF",
      "H1HA",
      "hHER2",
      "1-20",
      "Trastuzumab",
      "4-4-20",
      "clinical stage therapeutic",
      "H1-Solomon",
      "scFv",
      "VH1-69",
      "H1",
      "SARS-CoV-2-Wuhan",
      "Ixekuzimab",
      "mAb114UCA",
      "VK1-39",
      "cr6261",
      "Fv",
      "S309",
      "PDL2",
      "Eculizumab",
      "VHH",
      "Golimumab",
      "Syncytin2",
      "integrin alpha11",
      "Ebola-Virus-GP",
      "MEDI-UCA",
      "SARS-CoV-2 peptide",
      "IL36R",
      "FXI",
      "Osocimab",
      "germline",
      "ROBO1",
      "emibetuzumab",
      "REGN10987",
      "SA58",
      "fluorescein",
      "Afasevikumab",
      "Bimagrumab",
      "PDL1",
      "DKK1",
      "SARS-CoV-2-WT-S6P",
      "H9",
      "H7-HK16",
      "MEDI",
      "none",
      "XBB.1.5"
    ],
    "study": [
      "Biophysical properties of the clinical-stage antibody landscape",
      "Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows",
      "Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies",
      "Heparin chromatography as an in vitro predictor for antibody clearance rate through pinocytosis",
      "Unlocking de novo antibody design with generative artificial intelligence",
      "Machine learning optimization of candidate antibody yields highly diverse sub-nanomolar affinity antibody libraries",
      "AbRank: A Benchmark Dataset and Metric-Learning Framework for Antibody-Antigen Affinity Ranking",
      "Measuring the sequence-affinity landscape of antibodies with massively parallel titration curves",
      "none",
      "A dataset comprised of binding interactions for 104,972 antibodies against a SARS-CoV-2 peptide",
      "Efficient evolution of human antibodies from general protein language models",
      "Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen",
      "Retrospective SARS-CoV-2 human antibody development trajectories are largely sparse and permissive",
      "Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding",
      "High-Throughput Machine Learning-Aided Antibody Discovery for Cell Surface Antigens",
      "Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space",
      "An integrated technology for quantitative wide mutational scanning of human antibody Fab libraries",
      "Binding affinity landscapes constrain the evolution of broadly neutralizing anti-influenza antibodies",
      "Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus-related antibodies",
      "Automated optimisation of solubility and conformational stability of antibodies and proteins",
      "IgDesign: In vitro validated antibody design against multiple therapeutic antigens using inverse folding",
      "Unsupervised evolution of protein and antibody complexes with a structure-informed language model",
      "AVIDa-hIL6: A Large-Scale VHH Dataset Produced from an Immunized Alpaca for Predicting Antigen-Antibody Interactions",
      "A SARS-CoV-2 Interaction Dataset and VHH Sequence Corpus for Antibody Language Models",
      "Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces",
      "Antibody evolution constrains conformational heterogeneity by tailoring protein dynamics",
      "Humanization of antibodies using a machine learning approach on large-scale repertoire data",
      "Identifying developability risks for clinical progression of antibodies using high-throughput in vitro and in silico approaches",
      "Assisted Design of Antibody and Protein Therapeutics (ADAPT)",
      "NbThermo: a new thermostability database for nanobodies "
    ],
    "year": [
      2006,
      2017,
      2018,
      2019,
      2021,
      2022,
      2023,
      2024,
      2025
    ],
    "license": [
      "none",
      "Attribution-NonCommercial 4.0 International",
      "Attribution-NonCommercial-NoDerivatives 4.0 International",
      "Clear BSD",
      "Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License",
      "Attribution 4.0 International",
      "MIT License"
    ],
    "size": [
      137,
      43,
      97,
      128,
      13,
      1259701,
      1903928,
      342357,
      15,
      11052,
      5580,
      352140,
      81,
      17,
      14,
      20,
      8,
      21,
      12,
      16,
      22,
      23,
      50,
      182,
      28,
      27,
      31,
      2,
      1407,
      869,
      4276,
      18,
      56,
      70,
      52,
      53,
      34,
      29,
      45,
      39,
      48,
      51,
      24,
      126,
      96,
      1071,
      1040,
      953,
      921,
      32393,
      32768,
      427,
      141,
      5,
      422,
      47,
      40,
      127,
      36,
      33,
      19,
      49,
      7,
      30,
      573892,
      77004,
      2049,
      10970,
      94,
      217,
      132,
      130,
      112,
      113,
      115,
      6,
      86,
      10,
      192,
      673
    ]
  }
}